
A Thriller That's Most Fun When It's Boring
The biggest compliment I can give Last Breath, a gripping, workmanlike new movie about an undersea rescue, is that I would happily watch a version of it where absolutely nothing goes wrong. The director Alex Parkinson's debut dramatic film is based on his 2019 documentary of the same name; both recount an incident in the world of 'saturation diving,' in which a technician was stranded 300 feet under the North Sea. It's the kind of intense, rare, do-or-die emergency that's worthy of a hefty Hollywood feature. But I was mesmerized enough just watching these people do their very odd, high-stakes job.
The heroes of both Parkinson's original telling and the feature's re-creation are Chris Lemons (played by Finn Cole), Duncan Allcock (Woody Harrelson), and David Yuasa (Simu Liu): three deep-sea repairmen whose task is so unthinkably risky and weird, it's hard to imagine humans actually being able to carry it out. And yet, Parkinson carefully takes viewers through the chipper aplomb with which these men approach their profession. We see them as they're getting on a large boat in the North Sea, living in a pressurized habitat where they adjust to a helium-rich atmosphere, then hopping into a diving bell to go to the ocean floor and work on the pipes and systems lining it—these mysterious but vital structures that quietly underpin modern life.
The trio's occupation feels akin to the experience of traveling to space. They isolate themselves from their families for months on end, relocating to the most hostile environments imaginable. I'll admit that I've spent approximately zero minutes thinking about the giant gas lines and other such superstructures on the ocean floor until now, but once I understood what Last Breath was about, I was locked in. Parkinson's background as a documentarian serves the movie well; he lays out every aspect of this strange operation for the audience without making his story feel like a Wikipedia entry.
Last Breath 's story unfurls in ways that go beyond the simply factual—in large part because of its charming cast. I'm not too familiar with Cole (who is best known for his work on the TV show Peaky Blinders), but he's appropriately fresh-faced and lively as Lemons, the diving team's newest member. He's eager to learn the ropes from Harrelson's grizzled vet, Allcock; the latter actor can play this kind of wisecracking mentor in his sleep, but he's a reliably funny dispenser of exposition. As Yuasa, Liu also plays an archetype —the no-nonsense professional—but he keeps the character on the right side of curtness, underlining the extreme professionalism required in such a scary job.
I have no idea how Parkinson captured Last Breath 's underwater footage, which illustrates how dark, treacherous, and almost instantly frightening the deep sea is. This setting is not a place of wonder filled with peculiar flora and fauna, but a gaping, uninviting void. It's so inhospitable that the presence of big pipes and industrial manifolds comes across as traces left behind by ancient aliens. When Lemons produced a wrench to start tightening some screws, I almost laughed: How could a pipe in such a surreal location be in need of such mundane maintenance?
Of course, things do go wrong, which viewers familiar with the true story know well. A computer error on the ship that the divers are tethered to causes it to drift off course. In the ensuing chaos, Lemons's guideline (which gives him oxygen, power, and a chain to civilization) snaps, stranding him at the bottom of the ocean; he's left with just a few minutes of life support. What happens next as his colleagues and other members of the crew try to save him is unimaginable and nerve-racking. But it's also deeply, mesmerizingly process-oriented.
It would have been easy to inflate Last Breath 's action stakes to make them fun and absurd, but Parkinson's nonfiction instincts as a filmmaker won't really allow for that. I'm thankful for the meticulous realism that follows instead. Entire sequences are devoted to tasks as humdrum as rebooting a ship's computer (which involves untangling a lot of wires) and shepherding a little robotic sub to try retrieving Lemons, which resembles a very tense version of a fairground claw game. Harrelson and Liu have plenty of movie-star appeal, but the director tends to keep them in stasis; they're frequently parked in neutral as they figure out the best way back to their friend.
These scenes shouldn't be so riveting, but they are—the film makes an effort to invest the audience in the story's human concerns as much as in its more procedural elements. Last Breath is a midsize version of a large-scale thriller, one that isn't afraid to seem boring, and I mean that as a major compliment.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a day ago
- Yahoo
BioArctic to initiate next cohorts in exidavnemab Phase 2a study after positive safety review
STOCKHOLM, June 13, 2025 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) announced today that the interim safety review of the clinical Phase 2a study EXIST showed exidavnemab to be safe and well-tolerated, whereby the second dose cohorts will now be initiated. The EXIST study evaluates exidavnemab, a drug candidate being developed as a treatment for Parkinson's disease and Multiple System Atrophy (MSA). The first cohort in the ongoing clinical Phase 2a study EXIST evaluated a lower dose of exidavnemab compared to placebo in patients with Parkinson's disease. An interim safety review showed that exidavnemab was safe and well tolerated. The positive outcome will result in the initiation of two further cohorts, to evaluate a higher dose of exidavnemab in comparison with placebo in patients with Parkinson's disease as well as MSA. "Exidavnemab is BioArctic's second disease modifying treatment for severe brain diseases, building on a similar scientific approach as Leqembi®. Both originate from our antibody platform, selectively targeting aggregated, toxic misfolded proteins. I am pleased that the interim safety review of our phase 2a study EXIST of exidavnemab showed a good safety and tolerability profile as expected, supporting progression into higher doses in both Parkinson's disease and MSA," says Gunilla Osswald, CEO at BioArctic. The Phase 2a study EXIST (EXIdavnemab Synucleinopathy Trial), is a randomized, double-blinded, placebo-controlled study to evaluate the safety and tolerability of exidavnemab and its pharmacokinetic profile. In addition, a broad range of biomarkers will be evaluated in plasma, cerebrospinal fluid (CSF), and using digital measurements. Exidavnemab is being developed as a novel disease-modifying treatment for synucleinopathies such as Parkinson's disease and MSA. Exidavnemab is a monoclonal antibody (mAb) that selectively targets pathological alpha-synuclein aggregates, while sparing the physiological forms. Aggregated alpha-synuclein damages nerve cells, and by selectively binding and removing these aggregates, exidavnemab is intended to preserve nerve cell function and slow the disease. There is a large unmet medical need for slowing disease progression in diseases such as Parkinson's disease and MSA. Exidavnemab has recently been granted orphan drug designation (ODD) in the US and a positive opinion regarding orphan medicinal product designation (OD) in the EU for the treatment of MSA. This release discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that such investigational agents will successfully complete clinical development or gain health authority approval. This information is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact person below, on June 13, 2025, at 08:00 CET. For further information, please contact:Oskar Bosson, VP Communications and Investor RelationsE-mail: mailto: +46 70 410 71 80 About Exidavnemab Exidavnemab is a monoclonal antibody drug candidate that is designed to selectively target and eliminate pathological alpha-synuclein aggregates, while sparing the physiological forms. Aggregates of alpha-synuclein participate in neurodegenerative disorders including Parkinson's disease and Multiple System Atrophy (MSA). The goal is to develop a disease modifying treatment that stops or slow down the progression of alpha-synucleinopathies e.g. Parkinson's disease and MSA. BioArctic's phase 2a study EXIST with exidavnemab is ongoing since 2024. EXIST is an important step towards a proof-of-concept study focusing on the efficacy of the drug candidate. Exidavnemab has been granted orphan drug designation (ODD) in the US and a positive opinion regarding orphan medicinal product designation (OD) in the EU for the treatment of Multiple System Atrophy (MSA). About BioArctic AB BioArctic AB (publ) is a Swedish research-based biopharma company focusing on innovative treatments that can delay or stop the progression of neurodegenerative diseases. The company is the originator of Leqembi® (lecanemab) – the world's first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer's disease. Leqembi has been developed together with Eisai. BioArctic has a broad research portfolio within Alzheimer's disease, Parkinson's disease, ALS and enzyme deficiency diseases. Several of the projects utilize the company's proprietary BrainTransporter™ technology, which improves the transport of drugs into the brain. BioArctic's B share (BIOA B) is listed on Nasdaq Stockholm Large Cap. For more information, please visit This information was brought to you by Cision The following files are available for download: BioArctic to initiate next cohorts in exidavnemab Phase 2a study after positive safety review View original content: SOURCE BioArctic Sign in to access your portfolio
Yahoo
2 days ago
- Yahoo
Seth Meyers Mocks Donald Trump's Relationship With Son Barron Trump
Seth Meyers on Wednesday cracked wise about President Donald Trump's bond with son Barron Trump. (Watch the video below.) 'In a new interview President Trump said that his children have a future in politics and added that his son Barron is, quote, 'very tall and good.' Nice,' the 'Late Night' host began. 'Sounds like Trump knows as much about Barron as your grandma knows about LeBron James.' Barron Trump, a 19-year-old NYU student, was credited with guiding his dad to the right podcast hosts to help him win the young male vote in the election. But in a previous interview the president hinted his youngest son's future may be outside of politics. 'He's got an unbelievable aptitude in technology,' Trump said. Meyers' monologue featured an additional dig that hinted Father's Day might not be Trump's best holiday. Excerpting another moment from Trump's recent podcast interview, the comedian said: 'Asked if his eldest son Donald Trump Jr. might run for president, Trump said that Don is 'a good guy' and added, quote, 'he's an outdoorsman.' 'Oh my god he talks about his kids like he's reading their Wikipedia profiles,' Meyers cracked. Fast-forward to 1:05 for Meyers' family segment: Melania Trump Breaks Silence On Whether Barron Was Rejected From Harvard Donald Trump Hints At Barron Trump's Future Career — And It May Surprise You NYU GOP Group's President Resigns After Calling Fellow Student Barron Trump An 'Oddity'


Tom's Guide
2 days ago
- Tom's Guide
When is 'The Phoenician Scheme' coming to streaming? Here's our best guess
Director Wes Anderson's latest movie is "The Phoenician Scheme," a dark comedy about wealthy international businessman Zsa-Zsa Korda (Benicio del Toro). Having narrowly dodged an assassination attempt, Korda appoints his daughter Liesl (Mia Threapleton) sole heir to his estate and embarks on a new enterprise, which puts them in the crosshairs of more dangerous foes. Anderson's summer movie is composed as precisely as ever, and was reasonably well-received by plenty of critics and moviegoers. At the time of writing, it's Certified Fresh on Rotten Tomatoes, with a 78% critics' rating and a slightly lower score (71%) from fans. In general, the consensus seems to be that "The Phoenician Scheme" is a typically stylish feature from the director, but it also isn't quite doing enough to stand alongside some of Anderson's absolute best movies. The movie first hit theaters at the end of May (with a nationwide release following one week later, on June 6), so we haven't gotten a confirmed streaming release date for "The Phoenician Scheme" just yet. Nevertheless, if you've decided not to see it in theaters and are waiting to watch it at home, here's our best guess at a potential "The Phoenician Scheme" streaming date. At the time of writing, the only way to watch "The Phoenician Scheme" is by seeing it in your local movie theater. Seeing as it only hit theaters at the end of May, that's probably going to be the only way to watch it for a little while yet, too. Plus, it won't come to streaming services straightaway, either; it'll first head to premium video-on-demand (PVOD) storefronts like Amazon. Get instant access to breaking news, the hottest reviews, great deals and helpful tips. Nevertheless, since the movie was distributed in the U.S. by Focus Features (a Universal subsidiary), we can at least expect "The Phoenician Scheme" to make its streaming debut on Peacock. It's important to bear in mind that we don't yet have a confirmed "The Phoenician Scheme" streaming date. However, looking back at how long it's usually taken Focus Features' other releases to arrive on streaming, I'd wager "The Phoenician Scheme" could come to Peacock in mid to late July 2025. That's based on the fact that we typically wait between six to eight weeks for Focus Features films to start streaming. For example, "Black Bag" arrived on Peacock on May 2, seven weeks after it hit theaters, while survival thriller "Last Breath" came to the streamer on April 25, eight weeks after its February 28 theatrical debut. However, if "The Phoenician Scheme" instead follows the release pattern of the acclaimed comedy-drama "The Ballad of Wallis Island," we might have to wait a bit longer for a streaming date. Tom Basden's endearing watch just hit the streamer on June 6, 10 weeks after its limited theatrical release on March 28. As soon as we get an official update (or a confirmed streaming date for "The Phoenician Scheme"), we'll be sure to share it here, so keep checking back.